Veracyte is trading 10.43% higher at $48.39, and the September 24, 2026 move remains unexplained.
- No company-specific announcement, analyst action, or other dated catalyst was identified; Veracyte’s press-release page lists no releases from September 22–24.
- The biotechnology sector is declining, so sector momentum does not explain the gain. The move may reflect trading activity or a delayed reaction to earlier news.